
Our Vision Build a versatile and modular platform to translate nuclear science into clinical medicine, delivering precision radiopharmaceuticals for diagnosing and treating various diseases. Our Mission Transform Nuclear Medicine into a mainstream Therapeutic Modality, unlocking new markets and improving patient outcomes. TRAIL A Platform for Development of Novel Theranostic Radioligands that Target both - Tumor-Specific Surface Proteins and DNA
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.